


## Taiwan develops high potent immunotherapy for COVID-19 Omicron variant

27 May 2022 | News

**To benefit high-risk people who are moderate to severely immunocompromised and lack adequate immunity responses despite COVID-19 vaccinations**



Taiwanese biotech firm, AcadeMab Biomedical Inc., has developed potentially life-saving monoclonal antibodies for COVID-19 patients using single B cell technology. The COVID-19 immunotherapies show the best neutralization ability (IC<sub>50</sub> = 11.4 and 4.3 ng/ml) in both Omicron variants BA.1 and BA.2 respectively.

AcadeMab's treatment specifically targets the SARS-CoV-2 Omicron variant. Studies conducted by AcadeMab have found high efficacy of their human monoclonal antibodies against the Omicron variant within 4 months.

In one of their studies, it was found that one human antibody showed the best neutralization ability (IC<sub>50</sub> = 11.4 and 4.3 ng/ml) in both Omicron variants BA.1 and BA.2 respectively.

"We've also seen broad-spectrum activity in our treatment against multiple circulating variants of concern (VOCs) announced by the World Health Organisation. Aside from its neutralizing efficacy against Omicron, this means it shows great potential to be a therapy of choice for patients infected with other COVID-19 variants aside from Omicron", said Pao-Yin Chiang, Ph.D., the lead scientist of single B cell platform at AcadeMab.

AcadeMab's cutting-edge technology using Single B cell technology will benefit high-risk people who cannot benefit fully from mere vaccination alone, are moderate to severely immunocompromised, and lack adequate immunity responses despite COVID-19 vaccinations.